AYA.AX stock falls 5.44% pre-market ASX 07 Apr 2026: quarterly target shows 39% upside

AYA.AX stock opened pre-market on 07 Apr 2026 at A$3.13, down 5.44% from yesterday’s close as traders test short-term support near the 50-day average. The move comes on 459,186 shares traded against a 30-day average of 499,074, signalling lighter-than-normal volume. Investors in Artrya Limited (AYA.AX) on the ASX will watch whether the AI-driven Salix product and upcoming catalysts restore confidence.

AYA.AX stock: pre-market price snapshot and intraday levels

AYA.AX stock is trading at A$3.13 in the pre-market on 07 Apr 2026, down A$0.18 for the session. The day range is A$3.03–A$3.40 and the stock opened at A$3.34. Volume today is 459,186 versus average volume 499,074, so liquidity is near average for ASX trading.

AYA.AX stock: company profile and AI positioning in healthcare

Artrya Limited (AYA.AX) is an Australian medical technology company based in West Perth. The firm sells Salix, a cloud AI tool for coronary computed tomography angiography used to flag coronary artery disease. The AI focus places Artrya in the Healthcare sector and the Medical – Healthcare Information Services industry on the ASX.

AYA.AX stock: fundamentals, valuation and cash metrics

Artrya reports EPS -0.17 and a trailing PE of -18.41, reflecting recent losses and early commercialisation. Market capitalisation is A$356,194,000.00 with 113,800,000 shares outstanding. Cash per share is A$0.61 and book value per share is A$0.71, giving a price-to-book near 4.41.

AYA.AX stock: technicals and trading signals

Technical indicators show neutral momentum with RSI 48.80 and MACD -0.04. The 50-day average is A$3.29 and the 200-day average is A$2.82, placing current price between these levels. Bollinger Bands sit A$2.62–A$3.62, so volatility is moderate with ATR A$0.27.

AYA.AX stock: Meyka AI grade and model forecasts

Meyka AI rates AYA.AX with a score of 63.998 out of 100 — Grade B — Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects monthly A$3.05, quarterly A$4.36, and yearly A$7.41. Versus the current price A$3.13, the model implies a monthly change of -2.56%, a quarterly upside of +39.30%, and a yearly upside of +136.67%. Forecasts are model-based projections and not guarantees.

AYA.AX stock: catalysts, risks and ASX timing

Key near-term catalysts include commercial adoption updates for Salix and the earnings announcement dated 27 Aug 2026. Major risks are continued negative margins, high R&D spend, and patchy revenue visibility. On the ASX, liquidity can compress around news, so watch average volume 499,074 when trading pre-market and open sessions.

Final Thoughts

AYA.AX stock trades at A$3.13 pre-market on 07 Apr 2026 as investors weigh execution against AI opportunity in cardiac imaging. Fundamentals show negative EPS -0.17 and stretched valuation metrics, but cash per share A$0.61 and tangible book value provide a balance sheet cushion. Technically, the stock sits near the 50-day average A$3.29 with neutral RSI 48.80. Meyka AI’s forecast model projects a quarterly level of A$4.36 (implied +39.30%) and a 12-month level near A$7.41 (implied +136.67%). These targets assume successful commercial traction for Salix and controlled operating spend. Use the ASX order book and volume signals before trading, and consult the company site and exchanges for updates. For more detail, see Artrya’s website and the ASX company page, and check our Meyka AI stock page for live data and model updates.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.